热门资讯> 正文
CureVac BV ð4 2023年盈利预览
2024-04-24 02:08
- CureVac BV (NASDAQ:CVAC) is scheduled to announce FQ4 earnings results on Wednesday, April 24th, before market open.
- The consensus EPS Estimate is -$0.15 and the consensus Revenue Estimate is $31.52M.
More on CureVac BV
- CureVac: No Momentum In Sight
- CureVac, MD Anderson team up for cancer vaccines
- CureVac posts early efficacy results for GSK-partnered flu shot
- Seeking Alpha’s Quant Rating on CureVac BV
- Historical earnings data for CureVac BV
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
